First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III , randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER 2- positive primary breast cancer. J BASELGA et al

• Eric-Charles ANTOINE (Paris)
• 20/01/2011